Journal
RADIOLOGY-CARDIOTHORACIC IMAGING
Volume 4, Issue 3, Pages -Publisher
RADIOLOGICAL SOC NORTH AMERICA (RSNA)
DOI: 10.1148/ryct.210205
Keywords
CT Angiography; Transcatheter Aortic Valve Implantation; Replace-ment (TAVI; TAVR); Cardiac; Outcomes Analysis; Cardiomyopa-thies; Left Ventricle; Aortic Valve
Funding
- Bayer
- Bracco
- Elucid Bioimaging
- Guerbet
- HeartFlow
- Siemens Healthcare
- Siemens Healthineers
- Siemens
Ask authors/readers for more resources
This study evaluated the value of using left ventricular long-axis shortening (LV-LAS) derived from coronary CT angiography (CCTA) to predict mortality in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR). The results showed that LV-LAS can independently predict mortality in patients undergoing TAVR, including those with a normal left ventricular ejection fraction (LVEF).
Purpose: To evaluate the value of using left ventricular (LV) long-axis shortening (LAS) derived from coronary CT angiography (CCTA) to predict mortality in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR). Materials and Methods: Patients with severe AS who underwent CCTA for preprocedural TAVR planning between September 2014 and December 2019 were included in this retrospective study. CCTA covered the whole cardiac cycle in 10% increments. Image series reconstructed at end systole and end diastole were used to measure LV-LAS. All-cause mortality within 24 months of follow-up after TAVR was recorded. Cox regression analysis was performed, and hazard ratios (HRs) are presented with 95% CIs. The C index was used to evaluate model performance, and the likelihood ratio X2 test was performed to compare nested models.Results: The study included 175 patients (median age, 79 years [IQR, 73-85 years]; 92 men). The mortality rate was 22% (38 of 175). When adjusting for predictive clinical confounders, it was found that LV-LAS could be used independently to predict mortality (ad-justed HR, 2.83 [95% CI: 1.13, 7.07]; P = .03). In another model using the Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM), LV-LAS remained significant (adjusted HR, 3.38 [95 CI: 1.48, 7.72]; P = .004), and its use improved the predictive value of the STS-PROM, increasing the STS-PROM C index from 0.64 to 0.71 (x2 = 29.9 vs 19.7, P = .001). In a subanalysis of pa-tients with a normal LV ejection fraction (LVEF), the significance of LV-LAS persisted (adjusted HR, 3.98 [95 CI: 1.56, 10.17]; P = .004).Conclusion: LV-LAS can be used independently to predict mortality in patients undergoing TAVR, including those with a normal LVEF. Supplemental material is available for this article.(c) RSNA, 2022
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available